Generali Asset Management SPA SGR Sells 6,369 Shares of Solventum Corporation $SOLV

Generali Asset Management SPA SGR lowered its stake in Solventum Corporation (NYSE:SOLV) by 58.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,619 shares of the company’s stock after selling 6,369 shares during the period. Generali Asset Management SPA SGR’s holdings in Solventum were worth $350,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Solventum by 0.7% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock valued at $1,500,000 after acquiring an additional 140 shares in the last quarter. Tradition Wealth Management LLC boosted its holdings in Solventum by 1.6% in the first quarter. Tradition Wealth Management LLC now owns 8,830 shares of the company’s stock valued at $671,000 after acquiring an additional 143 shares in the last quarter. Perigon Wealth Management LLC boosted its holdings in shares of Solventum by 3.8% during the 1st quarter. Perigon Wealth Management LLC now owns 4,352 shares of the company’s stock valued at $331,000 after buying an additional 159 shares in the last quarter. SouthState Corp boosted its holdings in shares of Solventum by 31.9% during the 1st quarter. SouthState Corp now owns 699 shares of the company’s stock valued at $53,000 after buying an additional 169 shares in the last quarter. Finally, HB Wealth Management LLC boosted its holdings in shares of Solventum by 5.6% during the 2nd quarter. HB Wealth Management LLC now owns 3,463 shares of the company’s stock valued at $263,000 after buying an additional 185 shares in the last quarter.

Solventum Stock Performance

Shares of Solventum stock opened at $72.11 on Friday. The stock has a market cap of $12.50 billion, a price-to-earnings ratio of 33.38, a PEG ratio of 2.94 and a beta of 0.50. The firm’s 50-day moving average is $72.63 and its 200 day moving average is $71.95. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. The company had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. Solventum’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Sell-side analysts anticipate that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on SOLV shares. Wall Street Zen cut shares of Solventum from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. UBS Group started coverage on shares of Solventum in a report on Wednesday, October 1st. They set a “neutral” rating and a $77.00 target price on the stock. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a report on Tuesday, July 1st. Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Finally, Jefferies Financial Group started coverage on shares of Solventum in a report on Thursday, September 11th. They set a “hold” rating and a $80.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $84.89.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.